

Original Article

Study of Immuno-physiological Alterations Induced by *Helicobacter Pylori* Infection Among Population in El-Baida City, Libya

Marfoua Ali* , Nagla Bait Almal, Manal Mohammed

Department of Zoology, Faculty of Sciences, University of Omar Al-Mukhtar, El-Baida, Libya

ARTICLE INFO

<https://doi.org/10.5281/zenodo.4425526>

* **Marfoua Ali:** Department of Zoology, Faculty of Sciences, University of Omar Al-Mukhtar, El-Baida, Libya
Tel.: (+218) 911498680
marfoua.saleh@omu.edu.ly

Received: 27-12-2020

Accepted: 06-01-2021

Published: 07-01-2021

Keywords: *H. pylori*, immuno-physiological alterations, El-Baida City, Libya.

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).
<http://creativecommons.org/licenses/by/4.0/>



ABSTRACT

Background. This work was carried out to investigate the changes in hematological and some physiological parameters among patients with *H. pylori* Admitted in El-Beida City, Libya. **Methods.** This study was carried out in 11 consecutive months (Oct 2018 to Aug 2019). A total of 181 adult patients were divided into two groups upon presence and absent of antibodies against to *H. pylori*. The positive group had 34 (60.7%) males, 102 (81.6%) females and the negative group had 22 (39.3%) males and 23 (18.4%) females. **Results.** Highest prevalence with positive *H. pylori* infection was noted in age group 20-50 years. Overall, 181 patients, 70.166 % cases were found positive with *H. pylori* in serum and 32.6% of cases were positive with *H. pylori* in stool. Most red blood parameters were significantly decreased in patients compared to control subjects. The numbers of white blood cells and percentage number of neutrophils were increased significantly in positive cases of *H. pylori* infection. A percentage value of lymphocytes was decreased significantly in positive cases. Results of platelets parameters were decreased in all subjects. In term of type of blood groups, the highest prevalence among individuals with blood group A, B and O. Mean levels of liver and kidney function parameters in the sera were in normal range all patients. In the current study, association of *H. pylori* infection with smoking, marital status and allergic disease were studied. Over positive cases 70.58 % of these cases were smoking. Upon marital status, *H. pylori* prevalence was higher in married subjects (65%) as compared to single subjects. And prevalence of non-allergic was higher in negative subjects with *H. pylori* as compared to positive subjects. **Conclusion.** *H. pylori* infection is usually lifelong therefore a positive test, physiological alteration usually denotes active infection unless the patient has received eradication therapy.

Cite this article: Ali M, Bait-Almal N, Mohammed M. Study of Immuno-physiological Alterations Induced by *Helicobacter Pylori* Infection Among Population in El-Baida City, Libya. *Alq J Med App Sci.* 2021;4(1):73-84.

INTRODUCTION

Helicobacter pylori (*H. pylori*), a gram-negative, helical bacilli that live in the gastric epithelium was first isolated in 1983 [1]. It is transmitted via the fecal-oral, gastro-oral, or oral-oral routes [2, 3]. It is able to thrive in the gastric environment due to urease [4], motility [5], and adherence to gastric epithelium [6, 7], which allow it to neutralize gastric acid, penetrate

through the mucus layer to the gastric epithelium, and colonize. Although infection with *H. pylori* persists without treatment, the majority of infections do not lead to symptoms or gastrointestinal disease (8, 9). In the 30 years that have elapsed since its discovery, more than 50 extragastric manifestations of *H. pylori* infection have been reported, involving a range of medical specializations including cardiology,

dermatology, endocrinology, gynecology and obstetrics, pneumology, neurology, odontology, ophthalmology, otorhinolaryngology, pediatrics, and hematology [10]. This human pathogen is known to induce several gastric disorders, but may also be associated with extragastric diseases like anaemia, dyspepsia, and some immunological disorders [11, 12]. It is important to note that of the extragastric diseases described in the medical literature that are possibly associated with *H. pylori*, only three such conditions have been incorporated into the guidelines: iron deficiency, vitamin B12 deficiency, and primary immune thrombocytopenic purpura. A negative association between *H. pylori* infection and asthma development has been observed. Studies with both children and adult subjects [13, 14] have reported a lower prevalence of *H. pylori* infection in asthmatic patients.

Earlier studies reported association between *H. pylori* presence in the liver and disease progression in those with viral chronic hepatitis and cirrhosis [15, 16]. In developing countries its prevalence reaches 75% in populations <20 years of age, and 90-100% in populations >50 years of age, without differences in gender distribution. It has been directly associated with gastroduodenal peptic ulcer, cancer, gastric lymphoma and with other entities such as nonulcer dyspepsia, lymphocytic gastritis, Menetrier's disease and protein-losing enteropathy [7].

Among Libyan population, the prevalence of *H. pylori* infection is not well known [17, 18]. The rate of infection in a group of dyspeptic patients reported to be around 82% [19]. Infection acquired early in childhood and reached up to 94% in older age [20]. Prevalence of *H. pylori* was significantly increased in association with marital status, education and low socioeconomic status [20, 21]. There is a lack recorder about this infection. In addition, no detailed study on such infection is being recorded so far in El-Baida City in Northeast of Libya. Therefore, the aim of this study was designed to study immuno-physiological alterations induced by *H. pylori* infection among population in El-Baida City, Libya.

METHODS

The study protocol was reviewed and approved by Bioethics Committee at Biotechnology Research Center (BEC-BTRC) with Ref No: BEC-BTRC 08-2018. Inclusion criteria involve: patients agreement participation in the study.

The study was performed between Oct 2018 to Aug 2019 at different private labs (Al-Raze Lab, Al-Mejher Lab and Al-Azher Lab) with Zoology department at Omar Al-Mukhtar University. One hundred and eighty one patients were enrolled in this study. All subjects (who included in this study) were diagnosed with gastrointestinal symptoms related to presence of *H. pylori*. Blood and stool samples were collected from each patient. At same time: questionnaire was answered from each patient including: age, sex, smoking habit, marital status and presence/absence of allergic.

Two blood samples were taken from each patient. One sample (2 ml) for all CBC tests was performed by automatic blood cell analyzer (XP-300 Automated Hematology Analyzer, Sysmex American, Inc. CBCs were performed on EDTA as anti-coagulated samples. The other sample (2 ml) was centrifuged at 3,000 rpm for 10 minutes to obtain serum. These serum samples were stored at -20°C until studied for other parameters. Host ABO and Lewis antigen phenotypes were determined with a macroscopic tube agglutination technique using commercially available murine anti-A, anti-B, anti-AB, anti-Lea and anti-Leb blood grouping reagents (Bioscot, Edinburgh, UK).

Level of IgG/IgM antibodies against *H. pylori* were investigated by enzyme-linked immunosorbent assay (ELISA) kit (Euroimmun Lübeck, Germany). Serum specimens were analyzed as described by the kit procedure. Level of IgG/IgM antibodies against *H. pylori* in stool were investigated by ELISA (Connex GmbH, Martinsried, Germany) method in stool specimens that were stored at -20°C. The results were analyzed spectrophotometrically. Absorbance was read at 450/650 nm.

Liver function parameters were estimated in all subjects by a commercially available test kits method on automatic analyzer from Biotechnologies, Germany with the manufacturer's instructions strictly adhered to using spectrophotometers (Humalyzer Junior). Determination of creatinine was based upon the Jaffe reaction with de-proteinization creatinine, in alkaline picrate solution forms a color complex), and serum urea which was determinate enzymatically by kits from Biomarhreb, Germany using spectrophotometer (Humalyzer Junior) for both tests [22].

Statistical analysis was carried out in Minitab software 17. Statistical significance was assessed using two samples T- test analysis after detection normal distribution to the data and appropriate $P < 0.05$ consider significant. The numerical data were shown as number and percentage. To find the significant difference between the observed variable studied, Pearson Chi-Square Test for Association was used, P value was taken as level of significance at <0.05 .

RESULTS

A total number of 181 patients (56 males (30.9%), 125 females (69.1%) were enrolled in this study. Upon this study 181 patients who positive with *H. pylori* infection was found 136 (75.12 %) and negative with *H. pylori* infection was 45 (24.86 %). Over all 181 patients who positive with *H. pylori* infection was found 34 (60.7%) and 102 (81.6%) for male and female respectively, as compared to negative subjects with *H. pylori* that found 22 (39.3%) and 23 (18.4%) for male and female respectively with significant deference between gender as shown in Table 1.

Results from distribution of cases upon smoking behavior in each gender separately were shown in same Table. In male subjects who were positive with *H. pylori* infection, 70.58 % of these cases were smokers and 28. 42% of them were non- smokers. Significant deference was found between percentage number smoking/non-smoking and positive cases for male subjects ($P=0.000$). Prevalence of non-allergic was

higher in negative subjects with *H. pylori* as compared to positive subjects. At same time, *H. pylori* prevalence was higher in female subjects 11.76% as compared to male subjects (5.88%). Non-significant deference was found between percentage number of allergic/non-allergic and positive cases for male/female subjects ($P=0.02$). *H. pylori* prevalence was higher in married subjects 60.78% and 64.7 % for female and male respectively as compared to single subjects. Non-significant deference was found between percentage number single/married and positive cases for male/female subjects ($P=0.06$) (Table 1).

Results from distribution of cases upon age groups in each gender separately, (as each group consist of 10 years intervals) were shown in Table 2. Highest prevalence with positive *H. pylori* infection was noted in age group 20-30 years followed by age groups 31-40 and 41-50 years in both gender. Lowest prevalence was observed in the age group of >60 years for both genders.

Table 1. Number and percentage of (sex, smoking habits, allergic condition, and marital status) among positive/negative *H. pylori* infection subjects

Items	Female No of cases (%)		Male No of cases (%)		P Value
	Negative with <i>H. Pylori</i>	Positive with <i>H. pylori</i>	Negative with <i>H. Pylori</i>	Positive with <i>H. pylori</i>	
Sex	23 (18.4)	102 (81.6)	22 (39.3)	34 (60.7)	0.002
Smoking	0	0	10 (45.5)	23 (70.6)	0.000
Non-Smoking	23 (100)	102 (100)	12 (54.5)	11 (29.4)	
Allergic	20 (87)	12 (11.8)	19 (87)	2 (5.9)	0.02
Non-Allergic	3 (13)	90 (88.2)	3 (13)	32 (94.1)	
Single	6 (26.1)	40 (39.2)	6 (27.3)	12 (35.1)	0.06
Married	17 (73.9)	62 (60.1)	16 (72.8)	22 (64.4)	

Table 2. Age distribution of male and female subjects

Age (Years)	Female No of cases (%)		Male No of cases (%)	
	Negative with <i>H. Pylori</i>	Positive with <i>H. pylori</i>	Negative with <i>H. Pylori</i>	Positive with <i>H. pylori</i>
<20	3 (13.04)	9(8.82)	3(13.63)	0
20-30	6(26.08)	43(42.15)	4(18.18)	13(38.23)
31-40	4(17.39)	27(26.47)	5(22.72)	12(35.29)
41-50	2(8.69)	16(15.68)	6(27.27)	5(14.70)
51-60	6(26.08)	7(6.86)	4(18.18)	3(8.82)
61-70	1(4.34)	0	0	0
>71	1(4.34)	0	0	1(2.94)

Total cases were tested for comparison between level of IgG and IgM antibodies against *H. pylori*




Figure 1. Percentage number of positive cases for levels of IgG and IgM against *H. pylori* from stool and serum

From stool and serum samples: The highest percentage of level of IgG antibody was found with serum followed by stool (Figure 1). While level of IgM antibody was found with serum followed by stool for female and male respectively. These levels were not significantly difference between level of two antibodies in each gender (P =0.306).

Comparison between percentage numbers of cases upon level of anti- *H. pylori* (IgG) antibodies in stool and serum samples among 181 subjects was illustrated in Table 3. Data from samples of stool/serum was divided to three categories upon level of IgG antibody against *H. pylori* infection: negative, equivocal and positive. Overall 181 patients, 32.596 % cases were found positive with *H. pylori* in stool and 3.9% of cases were equivocal. Overall 181

patients, 70.166 % cases were found positive with *H. pylori* in serum and 4.97 % of cases were equivocal with *H. pylori* infection. Percentage numbers of cases upon level of IgG anti-*H. pylori* was significantly difference in positive cases (serum or stool) comparison to negative cases.

Table 3. Levels of anti-*H. pylori* (IgG) antibodies of positive/negative cases in stool and serum samples

Three categories upon level of Antibody against <i>H. pylori</i>	Level of antibody (U/ml) Mean ±SEM	Number of case (%)	
Stool	Negative < 15 U/ml	5.47± 0.38*	115 (63.5)*
	Equivocal 15-20 U/ml	16.1±0.68*	7 (3.9)*
	Positive >20 U/ml	63.9±3.90	59(32.596)
Serum	Negative <0.75 U/ml	0.49±0.019*	45(24.862)*
	Equivocal 0.75-1 U/ml	0.79±0.017*	9(4.972)*
	Positive >1 U/ml	3.06±0.12	127(70.166)

Data are expressed as mean ± SEM. Within each level of antibody in serum/stool separately, means with different superscript (*) were significantly different at p<0.05. Where means without superscripts mean that there is no significant difference (p>0.05).

Values derived from CBC, including differential cell counts were recorded for each patient who positive cases of *H. pylori* infection compared to the values of patient who negative cases of *H. pylori* infection. Generally, the results were shown a lot of similarity between both genders in terms of effects. RBC counts were studied, and the results are shown in Table 4. The levels of HGB concentrations in the female and male who positive with *H. pylori* infection were significantly decreased compared to negative subjects with *H. pylori* infection. The presence of *H. pylori* had significant effect on the percent HCT. Values of MCH, MCHC and RDW (%) were also significantly lower in patients when compared with negative *H. pylori* subjects.

The WBC and Granulocytes were increased with significantly difference in female and male positive subjects with *H. pylori* (Table 5). However, percentage a level of Lymphocytes (%) was significantly

decreased both gender with positive *H. pylori* infection when compared with negative *H. pylori* infection subjects. Results of platelets are shown in Table 5. The mean PLT ($\times 10^3/\mu\text{l}$) number and the mean platelets volume MPV (%) in patients with *H. pylori* were decreased in both female and male subjects. Meanwhile PDW (%), PCT (%) and P-LCR (%) were also decreased without significant deference in both female and male subjects with *H. pylori* infection compared to negative subjects respectively.

Results of different blood groups were shown in Table 6. Overall subjects, the results were shown similarity with positive cases with *H. pylori* infection in both genders in term of type of blood groups. The lowest prevalence of was shown among subjects with blood group AB, and the highest prevalence among individuals with blood group A, B and O. Rh-positive subjects with *H. pylori* infection was higher than Rh-negative subjects at same blood group in both genders.

Table 4. Values of RBC, HGB, HCT, MCV, MCH, MCHC and RDW in positive/negative *H. pylori* infection subjects

Parameters	Female		Male	
	Negative with <i>H. Pylori</i>	Positive with <i>H. pylori</i>	Negative with <i>H. Pylori</i>	Positive with <i>H. pylori</i>
RBC ($\times 10^6/\mu\text{l}$)	4.595 \pm 0.10	4.389 \pm 0.045	5.065 \pm 0.076	5.010 \pm 0.15
HGB (g/dl)	13.11 \pm 0.34	11.88 \pm 0.19*	15.44 \pm 0.32	13.94 \pm 0.45*
HCT %	38.28 \pm 0.74	35.78 \pm 0.38*	43.38 \pm 0.70	39.77 \pm 1.1*
MCV (fL)	83.72 \pm 1.4	81.94 \pm 0.83	85.73 \pm 0.99	80.8 \pm 2.2**
MCH (pg)	28.63 \pm 0.61	27.16 \pm 0.34**	30.50 \pm 0.44	28.12 \pm 0.76*
MCHC (g/dL)	34.16 \pm 0.32	32.84 \pm 0.39*	35.56 \pm 0.31	34.81 \pm 0.34
RDW (%)	19.6 \pm 5.4	15.81 \pm 0.32	13.13 \pm 0.22	13.83 \pm 0.70

Data are expressed as mean \pm SEM. Within each parameter in each gender separately, means with different superscript (*) were significantly different at $p < 0.05$. Where means without superscripts mean that there is no significant difference ($p > 0.05$).

Table 5. Values of (WBC, Lymphocytes and neutrophil) and (PLT, MPV, PDW and PCT) in positive/negative *H. pylori* infection subjects.

Parameters	Female		Male	
	Negative with <i>H. Pylori</i>	Positive with <i>H. pylori</i>	Negative with <i>H. Pylori</i>	Positive with <i>H. pylori</i>
WBC ($\times 10^3/\mu\text{l}$)	6.71 \pm 0.42	8.23 \pm 0.32*	7.64 \pm 0.41	9.64 \pm 0.69*
Lymphocytes (%)	31.8 \pm 2.9	22.4 \pm 1.6*	31.44 \pm 2.0	24.4 \pm 2.3*
Neutrophil (%)	45.2 \pm 2.8	48.8 \pm 4.5	55.2 \pm 3.3	56.2 \pm 3.9
PLT ($10^9/\mu\text{l}$)	277.8 \pm 9.8	256.1 \pm 13	264.2 \pm 16	249.9 \pm 14
MPV (fL)	15.6 \pm 2.0	11.93 \pm 1.6	16.4 \pm 3.8	12.4 \pm 2.6
PDW (%)	12.11 \pm 0.81	11.46 \pm 0.38	11.43 \pm 0.54	9.97 \pm 1.3
PCT (%)	0.27 \pm 0.029	0.293 \pm 0.041	0.22 \pm 0.073	0.2235 \pm 0.017

Data are expressed as mean \pm SEM. Within each parameter in each gender separately, means with different superscript (*) were significantly different at $p < 0.05$. Where means without superscripts mean that there is no significant difference ($p > 0.05$).

Table 6. Blood group distribution among positive/negative *H. pylori* infection subjects

Blood groups	Female No of cases (%)		Male No of cases (%)	
	Negative with <i>H. Pylori</i>	Positive with <i>H. pylori</i>	Negative with <i>H. Pylori</i>	Positive with <i>H. pylori</i>
A-	0	7(6.86)	1(4.54)	2(5.88)
A+	10(43.47)	39(38.23)	3(13.63)	17(50)
B-	1(4.34)	4(3.92)	0	2(5.88)
B+	3(13.04)	18(17.64)	1(4.54)	3(8.82)
AB-	1(4.34)	1(0.98)	0	0
AB+	1(4.34)	4(3.92)	1(4.54)	2(5.88)
O-	2(8.69)	5(4.90)	3(13.63)	2(5.88)
O+	5(21.73)	24(23.52)	9(40.90)	6(17.64)

The effect of the presence of *H. pylori* infection on serum (AST, ALT and ALP) and (creatinine and urea) were shown in Table 7. All mean level values were in normal range in both gender. The results of the effect of symptoms related to *H. pylori* infection on kidney function parameters (creatinine and urea) were in normal range in female and male patients.

Table 7. Levels of (AST, ALT, and ALP) and (creatinine and urea) among positive/negative *H. pylori* infection subjects

Parameters	Female		Male	
	Negative with <i>H. Pylori</i>	Positive with <i>H. pylori</i>	Negative with <i>H. Pylori</i>	Positive with <i>H. pylori</i>
AST (U/L)	37.2± 2.6	37.95± 1.4	38± 2.7	42.3± 2.2
ALT (U/L)	36.6± 3.1	33.75± 2	37.1± 3.9	41.5± 3.2
ALP (U/L)	166.1±9.8	155± 9.1	168± 9.9	185.4±10
Creatinine (µg/dl)	0.78± 0.027	0.76± 0.026	0.80 ± 0.28	0.84± 0.026
Urea (mg/dl)	29.27± 1.6	28.05± 1.7	29.4± 1.7	29.2± 1.8

Data are expressed as mean ± SEM. Within each parameter in each gender separately, means with different superscript (*) were significantly different at $p < 0.05$. Where means without superscripts mean that there is no significant difference ($p > 0.05$).

DISCUSSION AND CONCLUSION

H. pylori represent one of the most common and medically important infections worldwide [23]. However, the prevalence varies greatly among countries and among population groups within the same country [24]. It occurs in at least half the world's population [25]. 181 was the total number of patients who were diagnosed with symptoms related to presence of *H. pylori* during months of study at El-Baida City.

In this study, both of genders appear to be equally exposed to *H. pylori* infection, since quite increase infection in female than males. This result agrees with other studies in Libya [17, 20, 26, 27] and in Egypt [28]. Disagree also with a meta-analysis showed that male gender is an issue related to increased prevalence for the infection of *H. pylori* [29]. The relationship between gender and *H. pylori* infection has been controversial in other studies [30, 31]. A systematic review with meta-analysis carried out in 2018 reported that no significant difference was observed between the two genders in worldwide *H. pylori* prevalence [32]. The role of sex to put males at significantly higher risk of *H. pylori* infection compared to females was observed in many previous studies at different countries [33-35].

Higher prevalence rates among females were similarly previously reported in many studies [25, 26, 34, 35].

The influence of lifestyle on prevalence of *H. pylori* infection remains controversial. Among the lifestyle habits common among male subjects; smoking showed a high association with *H. pylori* infection. Other authors also reported that smokers were at higher risk of acquiring *H. pylori* infection [26, 28, 36-38]. Smoking was implicated to promote virulent infection in individuals by inducing the expression of virulent genes, including *cag A* [39]. On the other hand, in most studies, there was no significant association between smoking and *H. pylori* infection [40, 41].

Upon marital status, *H. pylori* prevalence was higher in married subjects as compared to single subjects. In contrast of other studies from different society which reported that marital status, positively correlated with positive *H. pylori* seroprevalence, in Germany [42], in Turkey [38] and in Libya [20, 25-27]. This observation may refer to the modes of transmission of *H. pylori* or to stress in lifestyles.

In the current study, prevalence of non-allergic was higher in negative subjects with *H. pylori* as compared to positive subjects and this in line with previous study [43]. An issue to be considered in studies showing negative associations between *H. pylori* and various atopic and allergic diseases is that *H. pylori* positivity is linked with more crowded living conditions and poor hygiene in infancy [44].

Within the age range of 20 to 70 years, highest prevalence with positive *H. pylori* infection was noted in age group 20-30 years in both genders. This finding regularly was decreased with age up to an age of 70 years. This result is on contradictory to the findings of [26, 27, 45]. The most affected ages were between 20-50 and fewer than 60 in Benghazi [17], and in Tripoli (46).

Total cases were tested for comparison between level of IgG and IgM antibodies against *H. pylori* from stool and serum samples. According to this study, the

highest percentage of level of IgG/ IgM antibodies against *H. pylori* was noted with serum followed by stool for both gender. This is consistent with study in Zeliten City [27]. However, epidemiological surveys usually use serological tests for high sensitivity and specificity which will not limit the accuracy of prevalence estimates [47]. Most of the data available on the prevalence of *H. pylori* are unsatisfactory. Ag test were considered the gold standard method for diagnosis of *H. pylori* infection. Stool Ag test is attributed high sensitivity and specificity (up to 97%) [48] and its excellent positive and negative predictive values regardless of *H. pylori* prevalence [49]. Serological tests are also useful non-invasive methods for the diagnosis of *H. pylori* infection. They are acceptable by patients because of their non-invasiveness; quick results, less liability to be affected by antibiotics [50]. It is not also affected by those local changes in the stomach that could lead to a low bacterial load and to false negative results [51].

The RBC (parameters) levels were significantly lower in cases compared to controls for both male and female subjects. Similar observations were reported elsewhere [52]. Previous studies suggested a possible pathogenic mechanism of anemia and explained it by blood loss secondary to chronic erosive gastritis and decreased iron absorption secondary to chronic gastritis and hypochlorhydria [53, 54]. Valiyaveettil *et al.*, conducted [55] conducted a randomized controlled trial with 52 anemic adult patients undergoing upper gastrointestinal endoscopy; findings were suggestive of *H. pylori* eradication improving iron status. Four meta-analyses of randomized control trials have supported this association and also suggested a role of *H. pylori* in iron absorption [56-59]

When related to *H. pylori*, mean values of total WBC and percentage number of neutrophils were found significantly higher in positive cases compared to negative cases. Leukocytosis was reported to be high in *H. pylori* infected patients [60-62]. The elevation of WBC in *H. pylori* observed in infected cases may be attributed to increase production of inflammatory cytokines from epithelial cells in the gastric mucosa

[63]. Number of neutrophils is considered to be associated with formation, complexity, and activation of atheromatous plaque [64]. Consistent with the literature, the present study showed that the number of neutrophils increased in *H. pylori* infected subjects; moreover, the number of neutrophils increased as symptoms of *H. pylori* increased [60]. The decreasing in the percentage number of lymphocytes was found in this study. That was considered to be consistent with more increase in the number of neutrophils compared to that of lymphocytes and in the conditions associated with inflammation [60].

Results of platelets parameters were decreased without significant deference in both female and male subjects with *H. pylori* infection. In contrast of another study found that the rate of complete platelets response was low in *H. pylori*-positive patient [65-67]. *H. pylori* infection is a well-known cause of secondary ITP. The prevalence of *H. pylori* infection in patients with ITP is higher than age and gender matched healthy individuals [68]. Platelet count responses may occur independently of *H. pylori* infection as a result of the immune modulating effects of macrolide antimicrobials or the removal of other commensal bacteria [66].

In the current study, the highest prevalence was found among individuals with blood group A, B and O. Previous studies shown that a strong association between the O blood group and infection caused by *H. pylori* [69-71]. However, result from another study found no association between ABO blood group and presence of *H. pylori* infection [72]. Moreover, controversy exists in the literature in relation to the association of the non-secretor state and blood groups with *H. pylori* related peptic ulcer disease, with many studies measuring antibodies to *H. pylori* [73-78].

The mean levels of liver and kidney enzymes in the serum were found in normal values in *H. pylori* infection subjects. In agreement to our results, a recent study showed that all previous parameters were in normal range in *H. pylori* positive subjects [79]. However, these results disagree with study that reported there was significant difference between

both groups regarding AST and ALT between those with or without *H. pylori* infection [80, 81].

In summary, over the past year, the knowledge of *H. pylori* pathogenesis and disease development has been improved by the studies focusing on investigation of bacterial factors. Application of large-scale screening methods should have broad relevance to understanding *H. pylori* infection-mediated carcinogenesis.

Disclaimer

The article has not been previously presented or published.

Conflict of Interest

There are no financial, personal, or professional conflicts of interest to declare.

REFERENCES

- [1] Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet*. 1984;1(8390):1311-1315.
- [2] Bui D, Brown HE, Harris RB, Oren E. Serologic Evidence for Fecal-Oral Transmission of *Helicobacter pylori*. *The American journal of tropical medicine and hygiene* 2016;94(1):82-88.
- [3] Perry S, de la Luz Sanchez M, Yang S, Haggerty TD, Hurst P, Perez-Perez G. Gastroenteritis and transmission of *Helicobacter pylori* infection in households. *Emerging Infectious Diseases*. 2006;12(11):1701-1708.
- [4] O'Rourke J, Bode G. Morphology and ultrastructure In: Mobley HLT, Mendz GL, Hazell SL, editors. *Helicobacter pylori: physiology and genetics* Washington (DC): ASM Press; 2001.
- [5] Goodwin CS, Worsley BW. Microbiology of *Helicobacter pylori*. *Gastroenterology Clinical of North American*. 1993; 22(1):5-19.
- [6] Logan RP. Adherence of *Helicobacter pylori*. *Alimentary Pharmacology and Therapeutics*. 1996 Suppl 1:3-15.
- [7] Mobley HL. *Helicobacter pylori* factors associated with disease development. *Gastroenterology*. 1997;113(6 Suppl):S21-8.
- [8] Atherton JC, Peek RM, Jr., Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity in *vacA*, the vacuolating cytotoxin gene of *Helicobacter pylori*. *Gastroenterology*. 1997;112(1):92-99.
- [9] Vaira D, Vakil N, Rugge M, Gatta L, Ricci C, Menegatti M. Effect of *Helicobacter pylori* eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. *Gut*. 2003;52(11):1543-1547.
- [10] Campuzano-Maya G. Hematologic manifestations of *Helicobacter pylori* infection. *World journal of gastroenterology: WJG*. 2014;20(36): 12818–12838.
- [11] Kuo CH, Chen YH, Goh KL, Chang LL. *Helicobacter pylori* and Systemic Disease. *Gastroenterology Research and Practice* 2014;2014:358-494.
- [12] Smyk DS, Koutsoumpas AL, Mytilinaiou MG, Rigopoulou EI, Sakkas LI, Bogdanos DP. *Helicobacter pylori* and autoimmune disease: cause or bystander. *World Journal of Gastroenterology*. 2014;20(3):613-629.
- [13] Chen Y, Blaser M. *Helicobacter pylori* colonization is inversely associated with childhood asthma. *The Journal of infectious diseases*. 2008;198(4):553-560.
- [14] Corrado G, Luzzi I, Pacchiarotti C, Lucarelli S, Frediani T, Cavaliere M. *Helicobacter pylori* seropositivity in children with atopic dermatitis as sole manifestation of food allergy. *Pediatric allergy and immunology*. 2000;11(2):101-105.
- [15] Esmat G, El - Bendary M, Zakarya S, Ela M, Zalata K. Role of *Helicobacter pylori* in patients with HCV - related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: possible association with disease progression. *Journal of viral hepatitis*. 2012;19(7):473-479.
- [16] Rocha M, Avenaudo P, Menard A, Le Bail B, Balabaud C, Bioulac-Sage P. Association of *Helicobacter* species with hepatitis C cirrhosis with or without hepatocellular carcinoma. *Gut*. 2005;54(3):396-401.
- [17] Almehdawi K, Ali R. The Prevalence of *Helicobacter Pylori* Infection in Benghazi, Libya. *IOSR Journal of Dental Medical Sciences*. 2016;16(04):73-7.
- [18] Salih BA, Naji AM, Bushala, M, Tobji, R.. Serological diagnosis of *Helicobacter pylori* infection in

- individuals with gastritis and in normal controls (Abstract). . Jamahiria 3rd Conference on medical sciences 1996; Trpoli.
- [19] Bakka A, Mohammad M, Altayar M, Toboloi A, Gariena A, Boushala M. Helicobacter pylori infection among Libyan chronic dyspeptic patients in Benghazi. *Libyan Journal of Infectious Diseases* 2009;3:30-36.
- [20] Bakka AS, Salih BA. Prevalence of Helicobacter pylori infection in asymptomatic subjects in Libya. *Diagnostic Microbiology Infectious Disease*. 2002;43(4):265-268.
- [21] Mehmood K, Nadir A, Hasan F. Lower education status predicts higher seropositivity for Helicobacter pylori infection in Pakistan. *Annual Research & Review in Biology*. 2014;3734-3741.
- [22] Wilkinson JH. The principles and practice of diagnostic enzymology: E. Arnold; 1976.
- [23] Versalovic J. Helicobacter pylori: pathology and diagnostic strategies. *American journal of clinical pathology*. 2003;119(3):403-412.
- [24] Feldman R. Epidemiologic Observations And Open Questions About Disease And Infection Caused By Helicobacter Pylori. Achtman M, Serbaum S Helicobacter Pylori: Molecular And Cellular Biology. *Virtual*. 2001;1(1):29-51.
- [25] Parkin DM. International variation. *Oncogene*. 2004;23(38):6329-40.
- [26] Almrabet W, Elazomi A, Araibi E, Shebani B, Alrandu F, Kasheem R. The Prevalence Of Helicobacter Pylori Infections And The Assessment Of Some Related Factors Among Medical Technology Students. *European Journal Of Pharmaceutical And Medical Research*. 2019;6(12)(12):529-535.
- [27] Mohammed Aa, Tamalli M, Mahmoud AJ. Seroprevalence of Helicobacter pylori infection and its risk factors among adult patients suffering from gastrointestinal tract disorders in Zeliten city, Libya 6-2017:1 *المرج-مجلة العلوم والدراسات الإنسانية*
- [28] EL-Kady H. Screening for Helicobacter pylori infection among asymptomatic university students in Alexandria, Egypt, using noninvasive laboratory techniques. *International Journal of Current Microbiology and Applied Sciences I*. 2018;7(6):2136-55.
- [29] Peach HG, Pearce DC, Farish S. Helicobacter pylori-infection in an Australian regional city: prevalence and risk factors. *Medical Journal of Australia*. 1997;167(6):310-313.
- [30] Yordanov D, Boyanova L, Markovska R, Ilieva J, Andreev N, Gergova G. Influence of dietary factors on Helicobacter pylori and CagA seroprevalence in Bulgaria. *Gastroenterology Research and Practice*. 2017;2017.
- [31] Yu X, Yang X, Yang T, Dong Q, Wang L, Feng L. Decreasing prevalence of Helicobacter pylori according to birth cohorts in urban China. *Turk J Gastroenterol*. 2017;28(2):94-97.
- [32] Zamani M, Ebrahimitabar F, Zamani V, Miller W, Alizadeh - Navaei R, Shokri - Shirvani J. Systematic review with meta - analysis: the worldwide prevalence of Helicobacter pylori infection. *Alimentary pharmacology and therapeutics*. 2018;47(7):868-876.
- [33] Ibrahim A, Morais S, Ferro A, Lunet N, Peleteiro B. Sex-differences in the prevalence of Helicobacter pylori infection in pediatric and adult populations: systematic review and meta-analysis of 244 studies. *Digestive and Liver Disease*. 2017;49(7):742-749.
- [34] Omosor KI, Omosor OH, Ibeh IN, Adejumo BIG, Abdulkadir UI, Dimkpa U. Seroprevalence of Helicobacter pylori infection and risk factors among asymptomatic subjects in Delta state, Nigeria. *Advances in Microbiology*. 2017;7(9):641-652.
- [35] Valliani A, Khan F, Chagani B, Khuwaja AK, Majid S, Hashmi S. Factors associated with Helicobacter pylori infection, results from a developing country-Pakistan. *The Asian Pacific Journal of Cancer Prevention* 2013;14(1):53-56.
- [36] Alebie G, Kaba D. Prevalence Of Helicobacter Pylori Infection And Associated Factors Among Gastritis Students In Jigjiga University, Jigjiga, Somali Regional State Of Ethiopia. *Journal Bacteriol Mycol*. 2016;3(3):60- 70.
- [37] Hanafi MI, Mohamed AM. Helicobacter pylori infection: seroprevalence and predictors among healthy individuals in Al Madinah, Saudi Arabia. *The Journal of the Egyptian Public Health Association*. 2013;88(1):40-45.
- [38] Ozaydin N, Turkyilmaz SA, Cali S. Prevalence and risk factors of helicobacter pylori in Turkey: a nationally-representative, cross-sectional, screening

- with the 13 C-Urea breath test. *BMC Public Health*. 2013;13(1):1215.
- [39] Ghosh P, Bodhankar SL. Determination of risk factors and transmission pathways of *Helicobacter pylori* in asymptomatic subjects in Western India using polymerase chain reaction. *Asian Pacific Journal of Tropical Disease*. 2012;2(1):12-17.
- [40] Sodhi JS, Javid G, Zargar SA, Tufail S, Shah A, Khan BA, et al. Prevalence of *Helicobacter pylori* infection and the effect of its eradication on symptoms of functional dyspepsia in Kashmir, India. *Journal of gastroenterology & hepatology*. 2013;28(5):808-813.
- [41] Zhou X, Su J, Xu G, Zhang G. Accuracy of stool antigen test for the diagnosis of *Helicobacter pylori* infection in children: a meta-analysis. *Clinical and Research Hepatology Gastroenterol*. 2014;38(5):629-38.
- [42] Kuepper - Nybelen J, Thefeld W, Rothenbacher D, Brenner H. Patterns of alcohol consumption and *Helicobacter pylori* infection: results of a population - based study from Germany among 6545 adults. *Alimentary pharmacology & therapeutics*. 2005;21(1):57-64.
- [43] Fullerton D, Leicester A, Smith S. Environmental taxes. *National bureau of economic research*, 2008 0898-2937.
- [44] Amedei A, Codolo G, Del Prete G, de Bernard M, D'Elisio MM. The effect of *Helicobacter pylori* on asthma and allergy. *Journal of asthma allergy*. 2010;3(29):139-149.
- [45] Toyoshima O, Nishizawa T, Arita M, Kataoka Y, Sakitani K, Yoshida S. *Helicobacter pylori* infection in subjects negative for high titer serum antibody. *World journal of gastroenterology*. 2018;24(13):1419.
- [46] Altyar I, Abdalla AM, Abdalwahab SS, Abdalwahab SS. The Seroprevalence of *Helicobacter pylori* Infection in Tripoli (Libya). *Nature Science*. 2015;13(1):81-86.
- [47] Feldman R, Evans S. Accuracy of diagnostic methods used for epidemiological studies of *Helicobacter pylori*. *Alimentary pharmacology & therapeutics*. 1995;9:21-31.
- [48] Jekarl DW, An YJ, Lee S, Lee J, Kim Y, Park Y-J. Evaluation of a newly developed rapid stool antigen test using an immunochromatographic assay to detect *Helicobacter pylori*. *Japanese Journal of Infectious Diseases*. 2013;66(1):60-64.
- [49] Bakri MM. Prevalence of *Helicobacter pylori* infection and the incidence of ureA and clarithromycin resistance gene 23S rRNA genotypes status in Saudi Arabia. *Saudi journal of biological sciences*. 2013;20(1):75-78.
- [50] Kalali B, Formichella L, Gerhard M. Diagnosis of *Helicobacter pylori*: Changes towards the Future. *Diseases*. 2015;3(3):122-135.
- [51] Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F. Management of *Helicobacter pylori* infection--the Maastricht IV/Florence Consensus Report. *Gut*. 2012;61(5):646-664.
- [52] Mwafy SN, Afana WM. Hematological parameters, serum iron and vitamin B12 levels in hospitalized Palestinian adult patients infected with *Helicobacter pylori*: a case-control study. *Hematology, transfusion and cell therapy*. 2018;40(2):160-165.
- [53] Kilincalp S, Karaahmet F, Ustun Y, Coban S, Yuksel I. effects of gastric microenvironment on the management of iron deficiency anaemia. *Alimentary pharmacology & therapeutics*. 2014;39(5):551-552.
- [54] Muhsen K, Cohen D. *Helicobacter pylori* infection and iron stores: a systematic review and meta - analysis. *Helicobacter*. 2008;13(5):323-340.
- [55] Valiyaveetil AN, Hamide A, Bobby Z, Krishnan R. Effect of anti-*Helicobacter pylori* therapy on outcome of iron-deficiency anemia: a randomized, controlled study. *Indian journal of gastroenterology: official journal of the Indian Society of Gastroenterology*. 2005;24(4):155-157.
- [56] Huang X, Qu X, Yan W, Huang Y, Cai M, Hu B. Iron deficiency anaemia can be improved after eradication of *Helicobacter pylori*. *Postgraduate medical journal*. 2010;86(1015):272-278.
- [57] Qu X-H, Huang X-L, Xiong P, Zhu C-Y, Huang Y-L, Lu L-G. Does *Helicobacter pylori* infection play a role in iron deficiency anemia? A meta-analysis. *World journal of gastroenterology: WJG*. 2010;16(7):886.
- [58] Wenzhen Y, Yumin L, Kehu Y, Bin M, Quanlin G, Donghai W. Iron deficiency anemia in *Helicobacter pylori* infection: meta-analysis of randomized

- controlled trials. *Scandinavian journal of gastroenterology*. 2010;45(6):665-676.
- [59] Zhang Z-f, Ning Y, Gang Z, Lei Z, Ying Z, Wang L-x. Effect of *Helicobacter pylori* eradication on iron deficiency. *LWW*; 2010.
- [60] Farah R, Khamisy - Farah R. Association of neutrophil to lymphocyte ratio with presence and severity of gastritis due to *Helicobacter pylori* infection. *Journal of clinical laboratory analysis*. 2014;28(3):219-223.
- [61] Jafarzadeh A, Akbarpoor V, Nabizadeh M, Nemati M, Rezayati M. Total leukocyte counts and neutrophil-lymphocyte count ratios among *Helicobacter pylori*-infected patients with peptic ulcers: independent of bacterial CagA status. *Southeast Asian Journal of Tropical Medicine & Public Health*. 2013;44(1):82-88.
- [62] Yu Y-y, Cai J-t, Song Z-y, Tong Y-l, Wang J-h. The associations among *Helicobacter pylori* infection, white blood cell count and nonalcoholic fatty liver disease in a large Chinese population. *Medicine*. 2018;97(46).
- [63] Hua-Xiang H, Lam S-K, Huang X-R, Wong W-M, Leung S-Y, Yuen S-T. *Helicobacter pylori* infection is associated with increased expression of macrophage migratory inhibitory factor—by epithelial cells, T cells, and macrophages—in gastric mucosa. *The Journal of infectious diseases*. 2004;190(2):293-302.
- [64] Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Aldama G, Pizzi C, Quiles J. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. *Heart*. 2004;90(8):847-852.
- [65] Agin M, Kayar Y, Dertli R. The relationship between mean platelet volume and platelet levels of children with *Helicobacter pylori* and gastritis. *Przegląd gastroenterologiczny*. 2019;14(3):198-201.
- [66] Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Liu Y. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. *Haematologica is the journal of the Ferrata Storti Foundation*. 2009;94(6):850-856.
- [67] Baxendell K, Waleign S, Tesfaye M, Wordofa M, Abera D, Mesfin A. Association between infection with *Helicobacter pylori* and platelet indices among school-aged children in central Ethiopia: a cross-sectional study. *BMJ Open Journals, Epidemiology Research*. 2019;9(4):1-8.
- [68] Papagiannakis P, Michalopoulos C, Papalexi F, Dalampoura D, Diamantidis MD. The role of *Helicobacter pylori* infection in hematological disorders. *European journal of internal medicine*. 2013;24(8):685-690.
- [69] Alkout AM, Blackwell CC, Weir DM, Poxton I, Elton RA, Luman W. Isolation of a cell surface component of *Helicobacter pylori* that binds H type 2, Lewis (a), and Lewis (b) antigens. *Gastroenterology*. 1997;112(4):1179-1187.
- [70] Lin C-W, Chang Y-S, Wu S-C, CHENG K-S. *Helicobacter pylori* in gastric biopsies of Taiwanese patients with gastroduodenal diseases. *Japanese Journal of Medical Science Biology*. 1998;51(1):13-23.
- [71] Mattos L. Lewis, secretor and non-secretor phenotypes in patients infected or uninfected by the *Helicobacter pylori* bacillus. *Sao Paulo Medical Journal*. 2002;120(2):55-58.
- [72] Tadesse E, Daka D, Yemane D, Shimelis T. Seroprevalence of *Helicobacter pylori* infection and its related risk factors in symptomatic patients in southern Ethiopia. *BMC Research notes*. 2014;7(1):834.
- [73] Chesner I, Nicholson G, Ala F, Elliott TJ, Langman M. Predisposition to gastric antral infection by *Helicobacter pylori*: an investigation of any association with ABO or Lewis blood group and secretor status. *European journal of gastroenterology hepatology*. 1992;4(5):377-379.
- [74] Dickey W, Collins J, Watson R, Sloan J, Porter K. Secretor status and *Helicobacter pylori* infection are independent risk factors for gastroduodenal disease. *Gut*. 1993;34(3):351-353.
- [75] Heneghan MA, Moran AP, Feeley KM, Egan EL, Goulding J, Connolly CE. Effect of host Lewis and ABO blood group antigen expression on *Helicobacter pylori* colonisation density and the consequent inflammatory response. *FEMS Immunology and Medical Microbiology*. 1998;20(4):257-266.
- [76] Höök-Nikanne J, Sistonen P, Kosunen T. Effect of ABO blood group and secretor status on the

- frequency of *Helicobacter pylori* antibodies. Scandinavian journal of gastroenterology. 1990;25(8):815-818.
- [77] Mentis A, Blackwell C, Weir D, Spiliadis C, Dailianas A, Skandalis N. ABO blood group, secretor status and detection of *Helicobacter pylori* among patients with gastric or duodenal ulcers. *Epidemiology*. 1991;106(2):221-229.
- [78] Umlauft F, Keeffe E, Offner F, Weiss G, Feichtinger H, Lehmann E. *Helicobacter pylori* infection and blood group antigens: lack of clinical association. *American Journal of Gastroenterology*. 1996;91(10):2135-2138.
- [79] Zhao M-M, Krebs J, Cao X, Cui J, Chen D-N, Li Y. *Helicobacter pylori* infection as a risk factor for serum bilirubin change and less favourable lipid profiles: a hospital-based health examination survey. *BMC infectious diseases*. 2019;19(1):1-8.
- [80] Abo-Amer YE-E, Sabal A, Ahmed R, Hasan NFE, Refaie R, Mostafa SM. Relationship between *helicobacter pylori* infection and nonalcoholic fatty liver disease (Nafld) in a developing country: A cross-sectional study. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*. 2020;13:619-625.
- [81] Sumida Y, Kanemasa K, Imai S, Mori K, Tanaka S, Shimokobe H. *Helicobacter pylori* infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease. *Journal of gastroenterology*. 2015;50(9):996-1004.